Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2017

01-02-2017 | Original Article

Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn’s Disease

Authors: Paulo Gustavo Kotze, Mansur Paulo Saab, Bárbara Saab, Lorete Maria da Silva Kotze, Marcia Olandoski, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Maria de Lourdes Setsuko Ayrizono, Daniela de Oliveira Magro, Claudio Saddy Rodrigues Coy

Published in: Digestive Diseases and Sciences | Issue 2/2017

Login to get access

Abstract

Background

The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn’s disease (CD) still needs to be determined.

Aims

To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy.

Methods

This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded). Patients were allocated in two groups according to preoperative anti-TNF status. Surgical and medical complications were analyzed and subsequently compared between the groups.

Results

A total of 123 patients were included (71 with and 52 without preoperative anti-TNF). The groups were considered homogeneous, except for perianal CD, previous azathioprine, and stomas. There was no significant difference between the groups regarding overall surgical complications (32.69% in anti-TNF− vs. 39.44% in anti-TNF+ patients, p = 0.457) or overall medical complications (21.15 vs. 21.13%, respectively, p = 1.000). In univariate analysis, previous steroids, perianal CD, and stomas were considered risk factors for surgical complications, and previous steroids and hypoalbuminemia for medical complications. In multivariate analysis, previous steroids were associated with higher rates of surgical and medical complications, while hypoalbuminemia was associated with higher medical complication rates.

Conclusions

There was no influence of the previous use of anti-TNF agents in postoperative surgical and medical complication rates in elective intestinal resections for CD. Previous steroids and hypoalbuminemia were associated with higher complication rates. This was the first case series of the literature describing outcomes in exclusively elective operations.
Literature
2.
go back to reference Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis-factor alfa for Crohn´s disease. N Engl J Med. 1997;337:1029–1035.CrossRefPubMed Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis-factor alfa for Crohn´s disease. N Engl J Med. 1997;337:1029–1035.CrossRefPubMed
3.
go back to reference Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn´s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn´s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.CrossRefPubMed
4.
go back to reference Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn´s Disease. N Engl J Med. 2004;350:876–885.CrossRefPubMed Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn´s Disease. N Engl J Med. 2004;350:876–885.CrossRefPubMed
5.
go back to reference Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn´s disease: evidence for and against current therapies. Aliment Pharmacol Ther. 2006;25:3–12. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn´s disease: evidence for and against current therapies. Aliment Pharmacol Ther. 2006;25:3–12.
6.
go back to reference Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.CrossRefPubMed Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.CrossRefPubMed
7.
go back to reference El-Hussuna A, Andersen J, Bisgaard T, et al. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn’s disease. Scand J Gastroenterol. 2012;47:662–668.CrossRefPubMed El-Hussuna A, Andersen J, Bisgaard T, et al. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn’s disease. Scand J Gastroenterol. 2012;47:662–668.CrossRefPubMed
8.
go back to reference Papaconstantinou I, Zeglinas C, Gazouli M, et al. Effect of infliximab on the healing of intestinal anastomosis. An experimental study in rats. Int J Surg. 2014;12:969–975.CrossRefPubMed Papaconstantinou I, Zeglinas C, Gazouli M, et al. Effect of infliximab on the healing of intestinal anastomosis. An experimental study in rats. Int J Surg. 2014;12:969–975.CrossRefPubMed
9.
go back to reference Strebel K, Nielsen SR, Biagini M, Qvist N. Effect of Humira® on intestinal anastomotic response in rabbits. J Invest Surg. 2015;28:167–172.CrossRefPubMed Strebel K, Nielsen SR, Biagini M, Qvist N. Effect of Humira® on intestinal anastomotic response in rabbits. J Invest Surg. 2015;28:167–172.CrossRefPubMed
10.
go back to reference Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008;12:1738–1744.CrossRefPubMed Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008;12:1738–1744.CrossRefPubMed
11.
go back to reference Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol. 2013;108:583–593.CrossRefPubMed Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol. 2013;108:583–593.CrossRefPubMed
12.
go back to reference Nasir BS, Dozois EJ, Cima RR, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg. 2010;14:1859–1865.CrossRefPubMed Nasir BS, Dozois EJ, Cima RR, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg. 2010;14:1859–1865.CrossRefPubMed
13.
go back to reference Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn’s disease—a nationwide cohort study. Aliment Pharmacol Ther. 2013;37:214–224.CrossRefPubMed Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn’s disease—a nationwide cohort study. Aliment Pharmacol Ther. 2013;37:214–224.CrossRefPubMed
14.
go back to reference Waterman M, Xu W, Dinani A, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut. 2013;62:387–394.CrossRefPubMed Waterman M, Xu W, Dinani A, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut. 2013;62:387–394.CrossRefPubMed
15.
go back to reference Myrelid P, Marti-Gallostra M, Ashraf S, et al. Complications in surgery for Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg. 2014;101:539–545.CrossRefPubMed Myrelid P, Marti-Gallostra M, Ashraf S, et al. Complications in surgery for Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg. 2014;101:539–545.CrossRefPubMed
16.
go back to reference El-Hussuna A, Krag A, Olaison G, Bendtsen F, Gluud LL. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn’s disease: a systematic review. Dis Colon Rectum. 2013;56:1423–1433.CrossRefPubMed El-Hussuna A, Krag A, Olaison G, Bendtsen F, Gluud LL. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn’s disease: a systematic review. Dis Colon Rectum. 2013;56:1423–1433.CrossRefPubMed
17.
go back to reference Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013;7:853–867.CrossRefPubMed Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013;7:853–867.CrossRefPubMed
18.
go back to reference Yang ZP, Hong L, Wu Q, Wu KC, Fan DM. Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis. Int J Surg. 2014;12:224–230.CrossRefPubMed Yang ZP, Hong L, Wu Q, Wu KC, Fan DM. Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis. Int J Surg. 2014;12:224–230.CrossRefPubMed
19.
go back to reference Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1057–1064.CrossRefPubMed Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1057–1064.CrossRefPubMed
20.
go back to reference Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487–496.CrossRefPubMedPubMedCentral Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487–496.CrossRefPubMedPubMedCentral
21.
go back to reference Brouquet A, Maggiori L, Zerbib P et al. Anti-TNF therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group. Oral presentation 027, ECCO congress, 2016, Amsterdam [abstract]. Brouquet A, Maggiori L, Zerbib P et al. Anti-TNF therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group. Oral presentation 027, ECCO congress, 2016, Amsterdam [abstract].
23.
go back to reference Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn’s disease patients. World J Surg. 2009;33:1049–1052.CrossRefPubMed Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn’s disease patients. World J Surg. 2009;33:1049–1052.CrossRefPubMed
24.
go back to reference Kotze PG, Coy CSR. The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn’s disease: controversy still persists. Am J Gastroenterol. 2014;109:139.CrossRefPubMed Kotze PG, Coy CSR. The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn’s disease: controversy still persists. Am J Gastroenterol. 2014;109:139.CrossRefPubMed
25.
go back to reference Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320–326.CrossRefPubMed Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320–326.CrossRefPubMed
26.
go back to reference Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, Dozois EJ, Loftus EV. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis. 2016. [Epub ahead of print]. Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, Dozois EJ, Loftus EV. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis. 2016. [Epub ahead of print].
Metadata
Title
Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn’s Disease
Authors
Paulo Gustavo Kotze
Mansur Paulo Saab
Bárbara Saab
Lorete Maria da Silva Kotze
Marcia Olandoski
Lilian Vital Pinheiro
Carlos Augusto Real Martinez
Maria de Lourdes Setsuko Ayrizono
Daniela de Oliveira Magro
Claudio Saddy Rodrigues Coy
Publication date
01-02-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4400-2

Other articles of this Issue 2/2017

Digestive Diseases and Sciences 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.